Type I Interferon Signatures in Systemic Lupus

From Nucleic-Acid Complexes to an Interferon Signature

In systemic lupus erythematosus (SLE), self-derived nucleic acids can participate in a network that links innate sensing to broad immune activation. RNA- or DNA-containing material released during cell turnover may associate with autoantibodies to form immune complexes. When such complexes are taken up by susceptible innate immune cells, their nucleic-acid cargo can reach intracellular sensors and promote type I interferon (IFN) production. The resulting IFN signal changes gene expression in multiple cell types, creating an interferon-stimulated gene (ISG) signature that may be measured in blood or tissue.

For QSP, the important point is not that every patient follows one identical chain. It is that a mechanistic network can connect a source of nucleic-acid material, its immune-complex-mediated delivery, IFN production and clearance, and downstream cellular responses. This makes it possible to ask what a persistent ISG pattern supports—and what it does not establish about the current state of the system.

A Lupus-Relevant Mechanistic Network

A useful starting point is the source of nucleic-acid-containing material. Cell death and other forms of cellular damage can release self RNA and DNA. Autoantibodies can bind some of this material, forming complexes that alter its uptake and intracellular delivery. Plasmacytoid dendritic cells (pDCs) are one important potential source of type I IFN in this setting. Uptake of complexes through Fc receptors can deliver RNA or DNA to endosomal compartments, where Toll-like receptor 7 (TLR7) preferentially senses RNA-containing material and TLR9 senses DNA-containing material. Sensor engagement can activate transcriptional programs that produce type I IFNs, including IFN-α.

This route is not exclusive. Other cell types and nucleic-acid sensing pathways can contribute, and the relative importance of each source may vary across patients and contexts. The network therefore should not be reduced to “one immune complex activates one cell type.” Rather, immune complexes are a plausible delivery mechanism that can increase access of self nucleic acids to innate sensors.

Secreted type I IFNs bind the type I IFN receptor, IFNAR, on many immune and non-immune cells. Receptor signaling commonly engages JAK–STAT pathways and induces ISGs. The affected genes can include antiviral effectors, chemokines, and regulators that alter antigen presentation and immune-cell function. Depending on cell type and context, the resulting state can support B-cell activation and differentiation, myeloid activation, and interactions between innate and adaptive immunity. These downstream effects are network connections, not proof that IFN alone is sufficient to produce each clinical manifestation.

The network can also contain reinforcing influences. IFN signaling may increase expression of components involved in nucleic-acid sensing or antigen presentation, while activated immune cells can contribute further inflammatory signals. Such feedback can amplify or prolong responses when nucleic-acid input persists. At the same time, removal of extracellular material, receptor and signal turnover, and regulatory pathways oppose continued activation. The observed signature reflects the balance of these inputs, feedbacks, and sinks.

A Compact QSP Representation

A simple model helps keep distinct the upstream input, circulating IFN activity, and the downstream signature. Let \(C\) denote the abundance of nucleic-acid immune complexes in normalized units, \(I\) the measured or effective type I IFN concentration, and \(S\) a normalized ISG signature, with \(S=0\) representing baseline and \(S=1\) the chosen response scale. One illustrative model is:

Here \(q_0\) is basal IFN production, \(q_C\) is the maximum additional production attributable to the complex-dependent input, \(K_C\) is the complex abundance giving half of that maximal input, and \(k_I\) is the first-order IFN removal rate. In the signature equation, \(K_I\) is the IFN concentration giving half-maximal induction in this simplified response function, and \(k_S\) controls how quickly the signature approaches its IFN-dependent target. The equations are schematic: they do not resolve individual cells, IFN subtypes, separate RNA and DNA inputs, or every regulatory process.

The assumptions are consequential. The first equation treats production as an instantaneous saturable function of \(C\) and removal as proportional to \(I\). The second treats signature induction as a saturable function of IFN and signature loss as first order. Parameters are assumed constant over the modeled period. Those assumptions can be useful for interpreting patterns, but must be checked against the question and data; they are not universal properties of lupus biology.

Worked Examples

Interpreting Persistence, Diagnostics, and Alternatives

A persistent ISG signature means that the sampled cells retain a pattern of IFN-responsive expression at the time of sampling. It does not necessarily mean that circulating IFN is continuously high. IFN may have fluctuated between measurements; tissue and blood concentrations may differ; the response may decay more slowly than the cytokine; or ongoing upstream input may repeatedly re-induce the program. A signature can also vary with cell composition: a blood sample containing different proportions of cell types can change its aggregate expression profile even if expression within each cell type is unchanged.

A QSP interpretation should therefore compare measurements that occupy different positions in the proposed network. These might include nucleic-acid-containing complexes, IFN protein or bioactivity, ISG expression, and relevant cell populations or activation markers. Agreement across layers can strengthen a mechanistic interpretation, but covariance alone does not establish causation. In particular, an ISG panel is a downstream readout and should not be treated as a direct assay of the amount or source of IFN.

Several checks help identify when the simple model is inadequate:

• Persistent signature with low measured IFN: consider sampling time, compartment differences, and slower downstream turnover before concluding that the pathway is inactive or that the assay is wrong.
• Different genes move in different directions: a single \(S\) may conceal gene-specific regulation, cell-type differences, or non-IFN influences on individual genes.
• Signature changes while IFN does not: investigate changing cell composition, altered responsiveness, and measurement variability rather than forcing the data to fit the one-input response equation.
• Similar IFN levels with different clinical patterns: consider network context and other disease mechanisms; a common pathway readout need not imply a common downstream outcome.

This mechanistic model complements, rather than replaces, alternatives such as a descriptive ISG score, a direct IFN measurement, or a more detailed cell-specific model. A score is efficient for summarizing a gene panel but cannot localize the source. A protein measurement is closer to the cytokine itself but may miss transient or compartmentalized activity. A detailed model may represent cell types, sensing routes, and feedback separately, but requires more data and identifiable parameters. The appropriate level depends on the question: pathway state, source mechanism, kinetics, or prediction under a defined perturbation.

The main limitation is structural uncertainty. The schematic equations assume one effective complex input, one IFN pool, and one aggregate signature. They omit distinct IFN subtypes, multiple cellular sources, detailed feedback, and patient-specific differences in immune-complex formation and response. Consequently, their numerical parameters should be treated as hypothetical unless estimated and validated for a specified context. Persistent IFN signatures are biologically informative, but they are not a stand-alone measure of disease severity or proof of a unique causal route.